We demonstrated that the presence of visceral metastases and the lack of trastuzumab administration in the metastatic setting apparently increase the likelihood of early BM in advanced HER2-positive breast cancer, and the 3-gene classifier does not improve their predictive value. Here, ERBB2 is linked to breast carcinoma.